Adamas Pharmaceuticals Inc ADMS Income Statement

Adamas pharmaceuticals inc (ADMS)

Income statement / Yearly

Dec'19	Dec'18	Dec'17	Dec'16	Dec'15	Dec'14	Dec'13	Dec'12
Revenues:
Total revenues
54,637	34,046	571	572	-	-	-	-
Product sales
-	-	-	-	0	-	-	-
License and grant revenue
-	-	-	-	1,916	-	-	-
Total net revenues
-	-	-	-	1,916	55,846	71,095	37,471
Costs and operating expenses:
Cost of product sales
2,469	633	17	0	-	-	-	-
Cost of product sales
-	-	-	-	0	-	-	-
Research and development
30,034	39,300	27,168	31,230	35,895	21,860	7,410	9,192
Selling, general and administrative, net
114,369	109,135	61,312	30,326	23,458	-	-	-
Total costs and operating expenses
146,872	149,068	88,497	61,556	-	-	-	-
General and administrative, net
-	-	-	-	-	15,472	6,667	8,330
Total costs and operating expenses
-	-	-	-	59,353	37,332	14,077	17,522
Loss from operations
-92,235	-115,022	-87,926	-60,984	-57,437	18,514	57,018	19,949
Interest and other income, net
-2,093	-3,115	-1,351	-811	-363	917	4,906	1,913
Interest expense
15,044	19,092	4,645	0	0	-	-	-
Loss before income taxes
-105,186	-130,999	-91,220	-60,173	-57,074	17,597	52,112	18,036
Benefit for income taxes
0	0	-1,730	-115	-5,272	7,374	1,191	300
Net loss
-105,186	-130,999	-89,490	-60,058	-51,802	10,223	50,921	17,736
Basic
-	-	-	-	-	8,968	33,068	11,441
Diluted
-	-	-	-	-	9,069	35,353	11,596
Basic (in dollars per share)
-	-	-	-	-	0.60	3.48	1.21
Diluted (in dollars per share)
-	-	-	-	-	0.53	2.99	1.17
Net loss per share, basic and diluted (in dollars per share)
-3.80	-4.87	-3.97	-2.77	-2.86	-	-	-
Basic (in shares)
-	-	-	-	-	14,837	9,506	9,488
Diluted (in shares)
-	-	-	-	-	17,107	11,806	9,924
Weighted average shares used in computing net loss per share, basic and diluted (in shares)
27,677	26,886	22,558	21,711	18,111	-	-	-
Product sales
Total revenues
54,637	34,046	568	0	-	-	-	-
License and grant revenue
Total revenues
0	0	3	572	-	-	-	-